Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ L in HIV Type 1--Infected Individuals Receiving Potent Antiretroviral Therapy
Open Access
- 1 August 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (3), 361-372
- https://doi.org/10.1086/431484
Abstract
Background. The CD4 T cell count recovery in human immunodeficiency virus type 1 (HIV-1)—infected individuals receiving potent antiretroviral therapyKeywords
This publication has 29 references indexed in Scilit:
- CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 YearsThe Swiss HIV Cohort StudyArchives of Internal Medicine, 2003
- Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studiesThe Lancet, 2002
- The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapyAIDS, 2002
- Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infectionAIDS, 2000
- Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort StudyThe Lancet, 2000
- T cell changes after combined nucleoside analogue therapy in HIV primary infectionAIDS, 1999
- Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort studyThe Lancet, 1999
- Patterns of T-Cell Repopulation, Virus Load Reduction, and Restoration of T-Cell Function in HIV-Infected Persons During Therapy With Different Antiretroviral AgentsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Positive Effects of Combined Antiretroviral Therapy on CD4 + T Cell Homeostasis and Function in Advanced HIV DiseaseScience, 1997
- Alterations in the Immune Response of Human Immunodeficiency Virus (HIV)-Infected Subjects Treated with an HIV-Specific Protease Inhibitor, RitonavirThe Journal of Infectious Diseases, 1996